AngioDynamics co-founder to lead Delcath
This article was originally published in Clinica
Liver cancer treatment specialist Delcath Systems has appointed Eamonn Hobbs president and CEO. Mr Hobbs will bring to the New York firm over 25 years' experience in interventional radiology, interventional cardiology and gastroenterology device industries. He co-founded AngioDynamics, where he was president and CEO until earlier this year. Mr Hobbs succeeds Richard Taney, who will continue to serve on Delcath's board of directors. The company is developing a system designed to deliver ultra-high doses of anti-cancer drugs to the liver, while preventing systemic side-effects associated with chemotherapy. It is currently enrolling patients in phase 2 and 3 clinical studies for treatment of liver cancers using melphalan.